AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2906380
Drug: Sydnocarb (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sydnocarb (10 mg X 2 in air or 30 mg X 5 in water)
Trial: 2906380
Drug: Sydnogluton (sydnocarb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sydnogluton (sydnocarb 30 mg + glutamic acid 0.25 g X 5 in cold water)
Trial: 2179222
Drug: Sildimac (new
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildimac (new drug delivery system for silver sulfadiazine)
Trial: 2179222
Drug: Silvadene cream
DrugBank: Silver sulfadiazine (DB05245)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silvadene cream 1% (twice-daily wound cleansing)
Trial: 28159782
Drug: Tenapanor (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenapanor (3 or 30 mg once daily or 1, 3, 10, or 30 mg twice daily)
Trial: 26115513
Drug: sertraline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sertraline plus mirtazapine
Trial: 19571597
Drug: sertraline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sertraline plus placebo
Trial: 24176228
Drug: Baobab fruit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baobab fruit extract (18.5 g and 37 g)
Trial: 11977360
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment
Trial: 17320021
Drug: Selective estrogen
RxNorm normalized name: Selective estrogen receptor modulator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective estrogen receptor modulators (SERMs) such as raloxifene
Trial: 11192308
Drug: Leucocyte‐depletion filters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucocyte‐depletion filters added to the CPB circuit (treatment group)
Trial: 4028627
Drug: Acifran 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acifran 100 mg t.i.d.
Trial: 4028627
Drug: Acifran 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acifran 300 mg t.i.d.
Trial: 30476108
Drug: Isavuconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isavuconazole (200 mg) administered three times daily for 2 days, then once daily.
Trial: 27312961
Drug: Home modifications
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home modifications (e.g., handrails, grab rails, outside lighting, edging for outside steps, slip-resistant surfacing)
Trial: 27097430
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine hemorrhoids lotion for fumigation
Trial: 27097430
Drug: 1 000
RxNorm normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 000 mL 1: 5 000 potassium permanganate solution for sitz bath
Trial: 23181832
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg folic acid
Trial: 23181832
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg folic acid
Trial: 23380913
Drug: Combined folic
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined folic acid groups (0.4 mg and 4 mg)
Trial: 14652439
Drug: Nimodipine 30
RxNorm normalized name: nimodipine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine 30 mg Q6H
Trial: 10224639
Drug: Self-management therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management therapy with choice of target (behavioral or cognitive)
Trial: 10224639
Drug: Self-management therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management therapy without choice of target
Trial: 10224639
Drug: Self-management therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management therapy with choice of target
Trial: 9085491
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg dose of ritanserin
Trial: 20884122
Drug: Praziquantel 40
RxNorm normalized name: PRAZIQUANTEL 40 mg in 1 mL ORAL SOLUTION [A Vial]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel 40 mg/kg
Trial: 6401550
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with niridazole 25 mg/kg and metrifonate 10 mg/kg
Trial: 6401550
Drug: Metrifonate 10
RxNorm normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metrifonate 10 mg/kg
Trial: 26856191
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline (HS) inhalation
Trial: 26856191
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline (IS) inhalation
Trial: 22530354
Drug: Etanercept (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (50 mg/week) + Teriparatide (20 mg)
Trial: 18502991
Drug: Timolol-dorzolamide fixed
RxNorm normalized name: dorzolamide / timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol-dorzolamide fixed combination (TDFC)
Trial: 18502991
Drug: Timolol-dorzolamide fixed
RxNorm normalized name: dorzolamide / timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol-dorzolamide fixed combination (TDFC) and Latanoprost 0.005%
Trial: 10215732
Drug: LAC (lansoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAC (lansoprazole 30 mg b.d., amoxycillin 500 mg b.d., clarithromycin 400 mg b.d. for 7 days)
Trial: 10215732
Drug: LACP (LAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LACP (LAC regimen plus polaprezinc 150 mg b.d. for 7 days)
Trial: 7869193
Drug: Luteinizing hormone-releasing
RxNorm normalized name: (6-D-Tryptophan)luteinizing hormone-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteinizing hormone-releasing hormone (LH‐RH) stimulation tests in children with NF‐1 and OPTs
Trial: 7869193
Drug: Luteinizing hormone-releasing
RxNorm normalized name: (6-D-Tryptophan)luteinizing hormone-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteinizing hormone-releasing hormone (LH‐RH) stimulation tests in children without OPTs (control group)
Trial: 1694235
Drug: Alternating chemotherapy
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating chemotherapy regimens (MOPP/ABVD; CAD plus MOPP plus ABV) combined with intermediate-dose radiation therapy (RT)
Trial: 621612
Drug: Chlorambucil stable
RxNorm normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorambucil stable dose (0.2 mg/kg/day) for 56 to 60 days
Trial: 621612
Drug: Chlorambucil increasing
RxNorm normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorambucil increasing doses (0.2 to 0.63 mg/kg/day) for 42 to 77 days
Trial: 621612
Drug: Prednisone (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (60 mg/m2 on alternate days)
Trial: 30422390
Drug: Praliciguat (15/30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praliciguat (15/30 mg, 20/40 mg, 30/40 mg, and weight-based)
Trial: 28695804
Drug: Calcium 600
RxNorm normalized name: Calcium 600
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium 600 mg/d + VitD3 800 U/d (group C)
Trial: 28695804
Drug: Calcium 600
RxNorm normalized name: Calcium 600
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium 600 mg/d + 25 hydroxyl vitamin D (25OHD) 0.25 μg/d (group D)
Trial: 26679652
Drug: 5.0 g
RxNorm normalized name: IODINE 5.0 g in 1 L TOPICAL SOLUTION [FS-104]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 g sucrose gel
Trial: 26679652
Drug: 5.0 g
RxNorm normalized name: IODINE 5.0 g in 1 L TOPICAL SOLUTION [FS-104]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 g metronidazole gel
Trial: 19091346
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg finasteride daily for at least 30 days before surgery
Trial: 17407636
Drug: Varenicline 1
RxNorm normalized name: varenicline 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline 1 mg twice daily (BID)
Trial: 18084743
Drug: Varenicline 1
RxNorm normalized name: varenicline 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline 1 mg BID
Trial: 11172832
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 mg three times daily for 7 weeks)
Trial: 9645591
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose inhaled fluticasone propionate (250 microg b.d.)
Trial: 8942333
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg kg‐1 during desflurane anaesthesia
Trial: 8942333
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg kg‐1 during isoflurane anaesthesia
Trial: 30784955
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (24 IU twice daily)
Trial: 18378374
Drug: Dopaminergic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopaminergic medication (on)
Trial: 18378374
Drug: Dopaminergic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopaminergic medication (off)
Trial: 16706961
Drug: Low-intensity warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity warfarin (target INR 1.5-2.0)
Trial: 12905053
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg Solu‐Medrol intravenously and 160 mg Depo‐Medrol intramuscularly, plus 80 mg Depo‐Medrol on the dural sac
Trial: 10977010
Drug: Oral calcium
RxNorm normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcium supplementation after 3 months of metformin therapy
Trial: 7488478
Drug: Wound infiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wound infiltration with ketorolac 30 mg in saline
Trial: 7488478
Drug: Wound infiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wound infiltration with ketorolac 30 mg with 0.25% bupivacaine
Trial: 7488478
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (ketorolac 60 mg i.m.)
Trial: 6124470
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg bromazepam
Trial: 6118830
Drug: 3.0 mg
RxNorm normalized name: TOBRAMYCIN 3.0 mg in 1 mL OPHTHALMIC SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 mg bromazepam
Trial: 26459358
Drug: FES treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FES treatment group (n = 16)
Trial: 21496936
Drug: Group MVB:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group MVB: zinc (20 mg), magnesium (250 mg), vitamin C (200 mg), vitamin E (100 mg), vitamin B1 (10 mg), B2 (10 mg), B6 (10 mg), biotin (200 μg), B12 (10 μg), folic acid (1 mg)
Trial: 21496936
Drug: Group MV:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group MV: zinc (20 mg), magnesium (250 mg), vitamin C (200 mg), vitamin E (100 mg)
Trial: 17718106
Drug: Zileuton CR,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zileuton CR, 1,200 mg twice daily
Trial: 17718106
Drug: Placebo CR,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo CR, twice daily
Trial: 11440290
Drug: Topical 0.5%
RxNorm normalized name: phenol topical 0.5% topical spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.5% fluorouracil once daily for up to 28 days
Trial: 11440290
Drug: Topical 5%
RxNorm normalized name: urea topical 5% topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5% fluorouracil twice daily for up to 28 days
Trial: 9505769
Drug: Intermittent bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent bolus of 5 ml of 0.375% bupivacaine hourly
Trial: 9505769
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 5 ml of 0.375% bupivacaine hourly
Trial: 7829766
Drug: Hydrocortisone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (20 mg, orally, twice daily)
Trial: 1832761
Drug: rilmenidine 1
RxNorm normalized name: rilmenidine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rilmenidine 1 mg/day
Trial: 2894164
Drug: rilmenidine 1
RxNorm normalized name: rilmenidine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rilmenidine 1 mg twice a day
Trial: 29883974
Drug: saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline infusion (placebo)
Trial: 27172830
Drug: Rotigotine (<8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine (<8 mg/24 h)
Trial: 25393877
Drug: Pentoxifylline (PTX),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX), Ursodeoxycholic acid (UDCA), and low-dose low molecular weight heparin (LMWH) for 8 weeks
Trial: 21084988
Drug: Cyanoacrylate injection
RxNorm normalized name: ethyl cyanoacrylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyanoacrylate injection (CI)
Trial: 18306109
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g Hsp-G administered every morning for 12 weeks (n = 9)
Trial: 18306109
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered every morning for 12 weeks (n = 10)
Trial: 17186321
Drug: Moderate concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate concentration contrast medium (300 mg I/ml)
Trial: 17186321
Drug: High concentration
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High concentration contrast medium (370 mg I/ml)
Trial: 12707842
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural group therapy programme (16 group sessions of 90 min each)
Trial: 12707842
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural group therapy programme
Trial: 29562806
Drug: Calcitriol therapy
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcitriol therapy
Trial: 3885979
Drug: Intravenous timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous timolol (54 patients)
Trial: 29402341
Drug: 19SP (finished
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 19SP (finished at pasture supplemented with 5 kg DM of concentrate per head daily for 100 days)
Trial: 29402341
Drug: 19LP (finished
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 19LP (finished at pasture supplemented with 5 kg DM of concentrate per head daily for 150 days)
Trial: 29402341
Drug: 24MO (finished
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24MO (finished indoors over the second winter on grass silage ad libitum plus 5 kg DM of concentrate per head daily)
Trial: 29402341
Drug: 21SP (finished
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21SP (finished at pasture, supplemented with 5 kg DM of concentrate per head daily for 60 days)
Trial: 29402341
Drug: 21LP (finished
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21LP (finished at pasture, supplemented with 5 kg DM of concentrate per head daily for 110 days)
Trial: 22357140
Drug: Inotuzumab ozogamicin
RxNorm normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inotuzumab ozogamicin 1.8 mg/m² intravenously over 1 hour every 3-4 weeks (initially 1.3 mg/m² for first three adults and three children)
Trial: 22357140
Drug: Inotuzumab ozogamicin
RxNorm normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inotuzumab ozogamicin (first course 1.3 mg/m²)
Trial: 15848699
Drug: Daclizumab dosing
RxNorm normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daclizumab dosing strategies
Trial: 15041394
Drug: No antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibody induction
Trial: 23161124
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care program
Trial: 7648980
Drug: Aspirin 350
RxNorm normalized name: aspirin 350 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 350 mg/day for two weeks
Trial: 7648980
Drug: Aspirin 1400
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 1400 mg/day for two weeks
Trial: 2744905
Drug: Intracoronary nicardipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary nicardipine (0.4 mg)
Trial: 25898472
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) progesterone in oil 100 mg daily
Trial: 25898472
Drug: Oral micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micronized progesterone followed by compounded vaginal progesterone 200 mg 3 times daily (OV)
Trial: 23141881
Drug: THC/CBD oromucosal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC/CBD oromucosal spray (n=39)
Trial: 23141881
Drug: THC oromucosal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC oromucosal spray (n=4)
Trial: 18699801
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 200 microg twice daily for 14 days
Trial: 2371597
Drug: Topical 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5-fluorouracil (5-FU)
Trial: 8815753
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (methylprednisolone and cyclophosphamide)
Trial: 8815753
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy vs Methylprednisolone
Trial: 1519208
Drug: Gemfibrozil 1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil 1,200 mg/day
Trial: 6395276
Drug: Cefonicid (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefonicid (1.0 g once daily intramuscularly or intravenously)
Trial: 6395276
Drug: Cefazolin (0.5‐1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (0.5‐1.0 g three times a day intramuscularly or intravenously)
Trial: 24766062
Drug: Secondary care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secondary care treatment
Trial: 16769235
Drug: Paroxetine (PXT)
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paroxetine (PXT) 30 mg tid for two weeks
Trial: 14740955
Drug: Formulations 1-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulations 1-15 (10^5-6 PFU/dose or 10^3.5-4.5 PFU/dose)
Trial: 9467328
Drug: Combined phototherapy/low-intensity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined phototherapy/low-intensity laser therapy (CLILT) at 2.5 Hz
Trial: 9467328
Drug: Combined phototherapy/low-intensity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined phototherapy/low-intensity laser therapy (CLILT) at 5 Hz
Trial: 9467328
Drug: Combined phototherapy/low-intensity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined phototherapy/low-intensity laser therapy (CLILT) at 20 Hz
Trial: 1593244
Drug: Active transdermal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active transdermal nicotine system
Trial: 3914023
Drug: PGI2 infusion
RxNorm normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PGI2 infusion (10 mg/kg.min for 24 hours)
Trial: 30590701
Drug: AGO2 loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGO2 loading with G-rich sequences
Trial: 24999670
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT)
Trial: 19931154
Drug: Propofol (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (loading dose of 1 mg/kg over 15 minutes followed by maintenance of 1 to 3 mg/kg per hour)
Trial: 19931154
Drug: Dexmedetomidine (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (loading dose of 1 microg/kg over 10 minutes followed by maintenance of 0.2 to 2.5 microg/kg per hour)
Trial: 19023429
Drug: 6% cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% cellulose sulfate vaginal gel
Trial: 12792790
Drug: 5'‐DFUR (460
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5'‐DFUR (460 mg/m(2)/day) + PSK (3 g/day)
Trial: 12792790
Drug: 5‐FU (115
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU (115 mg/m(2)/day) + PSK (3 g/day)
Trial: 8781697
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg of vaginal prostaglandin E2 as outpatient treatment
Trial: 8781697
Drug: Expectant management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expectant management with twice weekly surveillance tests
Trial: 6729259
Drug: Choline theophyllinate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline theophyllinate, 600 mg orally